How many, if any, cases of nervous system disorders have been reported because of A-C breast cancer chemotherapy? I'm 45 and had treatment at 39 and 40. I now experience a very exaggerated amount of ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low ...

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

The National Agency for Food and Drug Administration and Control (NAFDAC) has raised a public health alert over the circulation ...

A new drug, camizestrant, shows promise in delaying progression of aggressive breast cancer. This treatment uses blood ...

Denosumab (Prolia) is a leading treatment for osteoporosis, but the rapid bone loss that can occur after discontinuing the ...

Lilly reported phase 3 data on its oral SERD imlunestrant in patients who progressed on an aromatase inhibitor late last year. Roche is aiming to have data on giredestrant, its challenger for the ...

Health Nation Nation & World Drug-Defying Breast Cancers Spotted Early in Blood Test Study June 1, 2025 at 4:02 pm By GINA KOLATA ...

First-line therapy for HR+, HER2‑ advanced breast cancer is usually a cyclin-dependent kinase (CDK) 4 and 6 inhibitor drug plus an aromatase inhibitor (a type of hormone treatment).